Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
925 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03416179 | A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia(BRIGHT AML1019) | completed | Phase 3 | 730 | PfizerINDUSTRY | 22 | Apr 21, 2023 | clinicaltrials |
| NCT04410445 | Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence(PIVOT-12) | terminated | Phase 3 | 765 | Nektar Therapeutics |
| 17 |
| Apr 21, 2023 |
| clinicaltrials |
| NCT01337089 | Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain | completed | Phase 3 | 660 | Jazz PharmaceuticalsINDUSTRY | 18 | Apr 12, 2023 | clinicaltrials |
| NCT01361607 | Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer(SPRAY III) | completed | Phase 3 | 399 | Jazz PharmaceuticalsINDUSTRY | 10 | Apr 12, 2023 | clinicaltrials |
| NCT01424566 | A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer | completed | Phase 3 | 406 | Jazz PharmaceuticalsINDUSTRY | 13 | Apr 12, 2023 | clinicaltrials |
| NCT04920617 | DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma(VITALIZE) | recruiting | Phase 2 | 102 | ImmunoVaccine Technologies, Inc. (IMV Inc.)INDUSTRY | 10 | Apr 7, 2023 | clinicaltrials |
| NCT01126190 | Neugranin in Breast Cancer Participants Receiving Doxorubicin/Docetaxel(NEUGR-003) | completed | Phase 3 | 381 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 5 | Mar 28, 2023 | clinicaltrials |
| NCT02041533 | An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) | completed | Phase 3 | 541 | Bristol-Myers SquibbINDUSTRY | 26 | Mar 2, 2023 | clinicaltrials |
| NCT02609828 | Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy | completed | Phase 3 | 156 | PfizerINDUSTRY | 16 | Feb 16, 2023 | clinicaltrials |
| NCT02654340 | Biomarkers for Tuberous Sclerosis Complex (BioTuScCom)(TuScCom) | terminated | — | 20 | CENTOGENE GmbH RostockINDUSTRY | 8 | Feb 10, 2023 | clinicaltrials |
| NCT01673867 | Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC(CheckMate057) | completed | Phase 3 | 582 | Bristol-Myers SquibbINDUSTRY | 22 | Feb 8, 2023 | clinicaltrials |
| NCT02428842 | Biomarker Evaluation in Advanced Stage Cervical Cancer by an International Working Group. Tumor Stages (1B1 - 4)(BIO-RAIDs) | completed | N/A | 419 | Institut CurieOTHER | 5 | Jan 20, 2023 | clinicaltrials |
| NCT05553808 | Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1 | completed | Phase 2 | 105 | GlaxoSmithKlineINDUSTRY | 12 | Jan 19, 2023 | clinicaltrials |
| NCT02538666 | An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy(CheckMate 451) | completed | Phase 3 | 907 | Bristol-Myers SquibbINDUSTRY | 32 | Jan 5, 2023 | clinicaltrials |
| NCT01957176 | A Rollover Study to Provide Continued Treatment With Eltrombopag | completed | Phase 4 | 22 | Novartis PharmaceuticalsINDUSTRY | 12 | Dec 30, 2022 | clinicaltrials |
| NCT01642004 | Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017) | completed | Phase 3 | 272 | Bristol-Myers SquibbINDUSTRY | 21 | Dec 28, 2022 | clinicaltrials |
| NCT05659433 | Contrast-enhanced vs. B-mode Ultrasound-guided Percutaneous Biopsy of Retroperitoneal Tumors | completed | N/A | 160 | Iuliu Hatieganu University of Medicine and PharmacyOTHER | 1 | Dec 21, 2022 | clinicaltrials |
| NCT03091127 | Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe | completed | — | 705 | AmgenINDUSTRY | 11 | Dec 12, 2022 | clinicaltrials |
| NCT03090737 | Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer(CheckMate 907) | completed | Phase 2 | 129 | Bristol-Myers SquibbINDUSTRY | 5 | Dec 5, 2022 | clinicaltrials |
| NCT02703272 | A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma | terminated | Phase 3 | 72 | Janssen Research & Development, LLCINDUSTRY | 20 | Dec 2, 2022 | clinicaltrials |
| NCT00858364 | Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy | terminated | Phase 3 | 2,549 | AmgenINDUSTRY | 37 | Nov 30, 2022 | clinicaltrials |
| NCT01568866 | Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients(ENDEAVOR) | completed | Phase 3 | 929 | AmgenINDUSTRY | 27 | Nov 14, 2022 | clinicaltrials |
| NCT02409368 | An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC(Checkmate 171) | completed | Phase 2 | 812 | Bristol-Myers SquibbINDUSTRY | 13 | Nov 14, 2022 | clinicaltrials |
| NCT05568433 | New Biomarkers in the Intracystic Liquid of Inflammatory and Non-inflammatory Pancreatic Cysts | completed | — | 63 | Iuliu Hatieganu University of Medicine and PharmacyOTHER | 1 | Oct 5, 2022 | clinicaltrials |
| NCT02128958 | Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 78 | Can-Fite BioPharmaINDUSTRY | 5 | Oct 4, 2022 | clinicaltrials |
| NCT01335399 | Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma(ELOQUENT - 1) | completed | Phase 3 | 748 | Bristol-Myers SquibbINDUSTRY | 20 | Sep 30, 2022 | clinicaltrials |
| NCT02412878 | Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma(ARROW) | completed | Phase 3 | 478 | AmgenINDUSTRY | 20 | Sep 23, 2022 | clinicaltrials |
| NCT01001377 | ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer | completed | Phase 3 | 1,010 | AmgenINDUSTRY | 29 | Sep 21, 2022 | clinicaltrials |
| NCT01080391 | Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma | completed | Phase 3 | 792 | AmgenINDUSTRY | 20 | Sep 21, 2022 | clinicaltrials |
| NCT02747043 | Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab(JASMINE) | completed | Phase 3 | 256 | AmgenINDUSTRY | 20 | Sep 10, 2022 | clinicaltrials |
| NCT01265849 | Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity(IT-MATTERS) | completed | Phase 3 | 928 | CEL-SCI CorporationINDUSTRY | 23 | Aug 19, 2022 | clinicaltrials |
| NCT01668784 | Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025) | completed | Phase 3 | 821 | Bristol-Myers SquibbINDUSTRY | 24 | Aug 9, 2022 | clinicaltrials |
| NCT02162667 | Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer | completed | Phase 3 | 562 | CelltrionINDUSTRY | 22 | Aug 3, 2022 | clinicaltrials |
| NCT00347412 | Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer | completed | Phase 3 | 903 | Cellectar Biosciences, Inc.INDUSTRY | 12 | Jul 25, 2022 | clinicaltrials |
| NCT02425891 | A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130) | completed | Phase 3 | 902 | Hoffmann-La RocheINDUSTRY | 40 | Jul 19, 2022 | clinicaltrials |
| NCT00966914 | Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin | completed | Phase 3 | 540 | BioNumerik Pharmaceuticals, Inc.INDUSTRY | 6 | Jul 13, 2022 | clinicaltrials |
| NCT02340221 | A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy(SANDPIPER) | terminated | Phase 3 | 631 | Hoffmann-La RocheINDUSTRY | 28 | Jul 12, 2022 | clinicaltrials |
| NCT03042611 | A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer(ANGEL) | completed | Phase 3 | 460 | Elevar TherapeuticsINDUSTRY | 12 | Jul 8, 2022 | clinicaltrials |
| NCT02200614 | Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer(ARAMIS) | completed | Phase 3 | 1,509 | BayerINDUSTRY | 36 | Jun 28, 2022 | clinicaltrials |
| NCT04389892 | Usefulness of Contrast Enhanced Harmonic Endoscopic Ultrasound for Pancreatic Cysts | completed | N/A | 58 | Iuliu Hatieganu University of Medicine and PharmacyOTHER | 1 | Jun 22, 2022 | clinicaltrials |
| NCT05418543 | CH-EUS in Diagnosis of Inoperable Bile Duct Tumors | unknown | N/A | 40 | Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian FodorOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT02625610 | Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) | completed | Phase 3 | 499 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 17 | Jun 9, 2022 | clinicaltrials |
| NCT04341909 | Trainee Involvement in ERCP Risk Score(TIERS) | completed | — | 1,283 | Clinical Hospital ColentinaOTHER | 1 | Jun 7, 2022 | clinicaltrials |
| NCT01239797 | Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma(ELOQUENT - 2) | completed | Phase 3 | 646 | Bristol-Myers SquibbINDUSTRY | 23 | Jun 1, 2022 | clinicaltrials |
| NCT00920816 | Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer | completed | Phase 3 | 492 | PfizerINDUSTRY | 14 | May 6, 2022 | clinicaltrials |
| NCT04328818 | Indwelling Device-associated Biofilms(BiofilmICU) | unknown | — | 150 | Grigore T. Popa University of Medicine and PharmacyOTHER | 1 | Mar 16, 2022 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials